RecruitingPhase 2NCT06925516

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Studying Heritable pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigator
Changzhen Shang, M.D, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Intervention
Apatinib and Adebrelimab in Combination With chemotherapy(drug)
Enrollment
38 target
Eligibility
18-75 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

Jiangsu HengRui Medicine Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06925516 on ClinicalTrials.gov

Other trials for Heritable pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Heritable pulmonary arterial hypertension

← Back to all trials